A Phase II evaluation of esorubicin in ovarian cancer: A Southwest Oncology Group study

David S Alberts, N. Mason-Liddil, D. Stock-Novack, R. V. O'Toole, T. M. Abbott, S. E. Salmon

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Patients with a pathologically confirmed diagnosis of metastatic or advanced epithelial-type ovarian carcinoma were entered into a Phase II trial of esorubicin. Eligibility criteria included measurable disease; performance status (SWOG) 0-2; no more than one prior chemotherapeutic regimen; and no prior doxorubicin therapy. The starting esorubicin dosing schedule was 30 mg/m2 every 3 weeks for good risk patients and 25 mg/m2 every 3 weeks for poor risk patients. Twenty-one patients were eligible for evaluation of response and toxicity to treatment. These patients received a median of 3 courses of esorubicin (range 1-13 courses). None of the 21 patients experienced a response to esorubicin. Median survival was 5.5 months. Leukopenia was the major toxicity. Eleven (79%) of the good risk patients and 2 (29%) of the poor risk patients experienced severe to life-threatening leukopenia. Mild to severe anemia was seen in 10 (71%) of the good risk patients and 7 (100%) of the poor risk patients. We conclude that esorubicin is ineffective in the treatment of ovarian cancer patients who have received primary chemotherapy.

Original languageEnglish (US)
Pages (from-to)146-149
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume15
Issue number2
StatePublished - 1992
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Leukopenia
esorubicin
Doxorubicin
Anemia
Appointments and Schedules
Therapeutics
Carcinoma
Drug Therapy
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Alberts, D. S., Mason-Liddil, N., Stock-Novack, D., O'Toole, R. V., Abbott, T. M., & Salmon, S. E. (1992). A Phase II evaluation of esorubicin in ovarian cancer: A Southwest Oncology Group study. American Journal of Clinical Oncology: Cancer Clinical Trials, 15(2), 146-149.

A Phase II evaluation of esorubicin in ovarian cancer : A Southwest Oncology Group study. / Alberts, David S; Mason-Liddil, N.; Stock-Novack, D.; O'Toole, R. V.; Abbott, T. M.; Salmon, S. E.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 15, No. 2, 1992, p. 146-149.

Research output: Contribution to journalArticle

Alberts, DS, Mason-Liddil, N, Stock-Novack, D, O'Toole, RV, Abbott, TM & Salmon, SE 1992, 'A Phase II evaluation of esorubicin in ovarian cancer: A Southwest Oncology Group study', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 15, no. 2, pp. 146-149.
Alberts, David S ; Mason-Liddil, N. ; Stock-Novack, D. ; O'Toole, R. V. ; Abbott, T. M. ; Salmon, S. E. / A Phase II evaluation of esorubicin in ovarian cancer : A Southwest Oncology Group study. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1992 ; Vol. 15, No. 2. pp. 146-149.
@article{9b4d9fbb8cdc4e0eadfddc5f90457b4a,
title = "A Phase II evaluation of esorubicin in ovarian cancer: A Southwest Oncology Group study",
abstract = "Patients with a pathologically confirmed diagnosis of metastatic or advanced epithelial-type ovarian carcinoma were entered into a Phase II trial of esorubicin. Eligibility criteria included measurable disease; performance status (SWOG) 0-2; no more than one prior chemotherapeutic regimen; and no prior doxorubicin therapy. The starting esorubicin dosing schedule was 30 mg/m2 every 3 weeks for good risk patients and 25 mg/m2 every 3 weeks for poor risk patients. Twenty-one patients were eligible for evaluation of response and toxicity to treatment. These patients received a median of 3 courses of esorubicin (range 1-13 courses). None of the 21 patients experienced a response to esorubicin. Median survival was 5.5 months. Leukopenia was the major toxicity. Eleven (79{\%}) of the good risk patients and 2 (29{\%}) of the poor risk patients experienced severe to life-threatening leukopenia. Mild to severe anemia was seen in 10 (71{\%}) of the good risk patients and 7 (100{\%}) of the poor risk patients. We conclude that esorubicin is ineffective in the treatment of ovarian cancer patients who have received primary chemotherapy.",
author = "Alberts, {David S} and N. Mason-Liddil and D. Stock-Novack and O'Toole, {R. V.} and Abbott, {T. M.} and Salmon, {S. E.}",
year = "1992",
language = "English (US)",
volume = "15",
pages = "146--149",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - A Phase II evaluation of esorubicin in ovarian cancer

T2 - A Southwest Oncology Group study

AU - Alberts, David S

AU - Mason-Liddil, N.

AU - Stock-Novack, D.

AU - O'Toole, R. V.

AU - Abbott, T. M.

AU - Salmon, S. E.

PY - 1992

Y1 - 1992

N2 - Patients with a pathologically confirmed diagnosis of metastatic or advanced epithelial-type ovarian carcinoma were entered into a Phase II trial of esorubicin. Eligibility criteria included measurable disease; performance status (SWOG) 0-2; no more than one prior chemotherapeutic regimen; and no prior doxorubicin therapy. The starting esorubicin dosing schedule was 30 mg/m2 every 3 weeks for good risk patients and 25 mg/m2 every 3 weeks for poor risk patients. Twenty-one patients were eligible for evaluation of response and toxicity to treatment. These patients received a median of 3 courses of esorubicin (range 1-13 courses). None of the 21 patients experienced a response to esorubicin. Median survival was 5.5 months. Leukopenia was the major toxicity. Eleven (79%) of the good risk patients and 2 (29%) of the poor risk patients experienced severe to life-threatening leukopenia. Mild to severe anemia was seen in 10 (71%) of the good risk patients and 7 (100%) of the poor risk patients. We conclude that esorubicin is ineffective in the treatment of ovarian cancer patients who have received primary chemotherapy.

AB - Patients with a pathologically confirmed diagnosis of metastatic or advanced epithelial-type ovarian carcinoma were entered into a Phase II trial of esorubicin. Eligibility criteria included measurable disease; performance status (SWOG) 0-2; no more than one prior chemotherapeutic regimen; and no prior doxorubicin therapy. The starting esorubicin dosing schedule was 30 mg/m2 every 3 weeks for good risk patients and 25 mg/m2 every 3 weeks for poor risk patients. Twenty-one patients were eligible for evaluation of response and toxicity to treatment. These patients received a median of 3 courses of esorubicin (range 1-13 courses). None of the 21 patients experienced a response to esorubicin. Median survival was 5.5 months. Leukopenia was the major toxicity. Eleven (79%) of the good risk patients and 2 (29%) of the poor risk patients experienced severe to life-threatening leukopenia. Mild to severe anemia was seen in 10 (71%) of the good risk patients and 7 (100%) of the poor risk patients. We conclude that esorubicin is ineffective in the treatment of ovarian cancer patients who have received primary chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0026511014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026511014&partnerID=8YFLogxK

M3 - Article

C2 - 1553903

AN - SCOPUS:0026511014

VL - 15

SP - 146

EP - 149

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 2

ER -